Tarsus Pharmaceuticals, Inc.

For the period ended Sep 30, 2025. Filed Nov 4, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 4, 2025

TARS$73.83+4.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

	Three Months EndedSeptember 30,		Nine Months EndedSeptember 30,
	2025	2024	2025	2024
Revenues:
Product sales, net	$118,697	$48,118	$299,692	$113,651
License fees and collaboration revenue	—	—	—	2,894
Total revenues	118,697	48,118	299,692	116,545
Operating expenses:
Cost of sales	8,309	3,242	19,757	7,900
Research and development	16,284	12,128	46,287	36,513
Selling, general and administrative	108,633	57,910	296,641	168,280
Total operating expenses	133,226	73,280	362,685	212,693
Loss from operations before other income (expense)	(14,529)	(25,162)	(62,993)	(96,148)
Other income (expense):
Interest income	4,114	4,120	11,797	11,367
Interest expense	(2,268)	(2,445)	(6,721)	(5,537)
Loss on debt extinguishment	—	—	—	(1,944)
Other income (expense), net	98	67	(128)	(179)
Total other income (expense), net	1,944	1,742	4,948	3,707
Net loss	$(12,585)	$(23,420)	$(58,045)	$(92,441)
Unrealized gain (loss) on marketable securities and cash equivalents	250	522	110	348
Comprehensive loss	$(12,335)	$(22,898)	$(57,935)	$(92,093)
Net loss per share, basic and diluted	$(0.30)	$(0.61)	$(1.40)	$(2.48)
Weighted-average shares outstanding, basic and diluted	42,607,717	38,381,968	41,457,027	37,286,911

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.